Authors


Jenna Wilke, NP

Latest:

Bridging Communication Gaps: Comprehensive Care for Upper GI Cancer Treatment

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.


Elizabeth Aronson, MSN, FNP-BCN, OCN

Latest:

Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma

Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.


Jonathan Goldman, MD

Latest:

Peripheral Neuropathy Treatable With Teliso-V in C–Met-High NSCLC

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.


Huntsman Cancer Institute at the University of Utah

Latest:

Five Researchers Awarded Pilot Project Funding

Every year, Huntsman Cancer Institute receives funding from the American Cancer Society to support the promising research of junior faculty.


Sarah Montini, BSN, RN, OCN

Latest:

Rx Road Map: Abemaciclib (Verzenio)

Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.



Nerina T. McDonald, PA-C

Latest:

Unlocking Bladder Cancer: A Guide to Effective Diagnosis and Staging

Experts share insights on standard work-up and staging practices for a patient with newly diagnosed bladder cancer.


Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP

Latest:

Hilda Haynes-Lewis and Rosaleen Bloom on Financial Toxicity and Workplace Stressors for Patients Undergoing Radiation

Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.


Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP

Latest:

Complementary Supportive Care Can Go Far for Patients With Cancer

Getting to the root of patients’ issues can provide support for their cancer journey through accessible means, says Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP.


Tim Cortese

Latest:

Tarlatamab Yields Response in Real-World ES-SCLC Population

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.


Hannah Clarke

Latest:

Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.


Melanie Darvish, BSN, RN

Latest:

Melanie Darvish on Receiving an ONS Scholarship and What it Means to Be An Oncology Nurse

Melanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.


David Hui, MD, MSc

Latest:

Many Patients Are Under-Sedated During End-of-Life Cancer Care

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses findings indicating that patients with agitated delirium may be under-sedated, in accordance with their personalized sedation goal.


Karyn A. Goodman, MD, MS

Latest:

Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer

Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.


John Lewandowski, PA-C, MS

Latest:

A Multidisciplinary Approach Improves a Patient’s Experience With Colon Cancer

Early coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.


Jun Zhang, MD, PhD

Latest:

Frontline Treatment Decisions in ALK+ NSCLC

Panelists discuss how treatment selection between lorlatinib and alectinib for ALK-positive non–small cell lung cancer (NSCLC) should consider both efficacy data favoring lorlatinib and patient-specific factors such as neuropsychiatric history or cardiovascular comorbidities that might favor alectinib.


Chad Robertson, PA-C

Latest:

Subcutaneous Daratumumab May Be More Feasible for Older Patients With MM

Subcutaneous daratumumab makes treatment a faster and more tolerable process for patients with multiple myeloma, according to an expert.


Diane Kennedy

Latest:

Support Systems and Multidisciplinary Treatment Approach

Panelists discuss City of Hope’s multidisciplinary approach, highlighting pharmacists providing medication guidance, social workers offering emotional support, and palliative care specialists managing symptoms, while consultants such as cardiologists and infectious disease experts address specific health issues to ensure coordinated, personalized care; complementary therapies such as acupuncture and mindfulness help manage adverse effects like neuropathy, and support groups foster community and resilience among patients and caregivers throughout their myeloma journey.


Estelamari Rodriguez, MD

Latest:

How I Counsel Patients About Lung Cancer Screening

A lung cancer screening navigator offers their perspective on shared decision-making.


Roman Fabbricatore

Latest:

ZEN-3694 Receives FDA Fast Track Status in Metastatic NUT Carcinoma

The investigational BET inhibitor is being investigated combined with abemaciclib or cisplatin/etoposide in NUT carcinoma in 2 clinical trials.


Sherry Adkins, MSN, ANP-C

Latest:

Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.


Katy Beckermann, MD, PhD

Latest:

Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.


Matthew Goetz, MD

Latest:

Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast Cancer

Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.


Ashley B. Johnson, MSN, APRN, FNP-C

Latest:

Considerations for Premenopausal Women With TNBC

Triple-negative breast cancer often occurs in women younger than 40.


Sarah Low, RN, MSN, OCN, CMSRN

Latest:

Low and Maldonado on Leveraging Wearable Devices to Improve Inpatient Ambulation

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.


Binod Dhakal, MD

Latest:

Life After CAR T Therapy: Insights for Patients and Referring Oncologists

This video segment focuses on key elements of patient education and support for long-term CAR-T survivors, strategies to maintain quality of life and manage late effects, differences in supportive care needs between ide-cel and cilta-cel recipients, and approaches to fostering collaboration between academic centers and community practices for optimal long-term care.


Brianna Lutz, MSN, RN, OCN

Latest:

Brianna Lutz on How to Improve Nurse Responsiveness on an Inpatient Oncology Unit

Brianna Lutz, MSN, RN, OCN, discusses a red-and-green dot hourly column that shows which patients with cancer have been attended to in the past hour.


Kelley A. Rone, DNP, RN, AGNP-c

Latest:

Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers

Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.


Courtney Flaherty

Latest:

Temferon Shows Early Signs of 3-Year Survival, Disease Control in GBM

Treatment with Temferon led to prolonged survival and possible disease control in 2 patients with newly diagnosed glioblastoma multiforme.


University of Arizona Cancer Center

Latest:

Cancer Center gets $1.1M gift for holistic cancer care

The gift is from the estate of Tom and Catherine Culley, longtime residents of the East Coast and worldwide travelers.